Categories: Muscle diseases, Neuronal diseases

Aliases & Classifications for Spasticity

MalaCards integrated aliases for Spasticity:

Name: Spasticity 53 29 6


Summaries for Spasticity

NINDS : 53 Spasticity is a condition in which there is an abnormal increase in muscle tone or stiffness of muscle, which might  interfere with movement, speech, or be associated with discomfort or pain.  Spasticity is usually caused by damage to nerve pathways within the brain or spinal cord that control muscle movement. It may occur in association with spinal cord injury, multiple sclerosis, cerebral palsy, stroke, brain or head trauma, amyotrophic lateral sclerosis, hereditary spastic paraplegias, and metabolic diseases such as adrenoleukodystrophy, phenylketonuria, and Krabbe disease. Symptoms may include hypertonicity (increased muscle tone), clonus (a series of rapid muscle contractions), exaggerated deep tendon reflexes, muscle spasms, scissoring (involuntary crossing of the legs), and fixed joints (contractures). The degree of spasticity varies from mild muscle stiffness to severe, painful, and uncontrollable muscle spasms. Spasticity can interfere with rehabilitation in patients with certain disorders, and often interferes with daily activities.

MalaCards based summary : Spasticity is related to primary lateral sclerosis, adult, 1 and spastic paraplegia 16, x-linked. An important gene associated with Spasticity is KIF7 (Kinesin Family Member 7). The drugs Acetylcholine and Ethanol have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and testes, and related phenotype is nervous system.

Wikipedia : 74 Spasticity (from Greek spasmos-, meaning 'drawing, pulling') is a feature of altered skeletal muscle... more...

Related Diseases for Spasticity

Diseases related to Spasticity via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 46)
# Related Disease Score Top Affiliating Genes
1 primary lateral sclerosis, adult, 1 10.4 SPG7 SPAST
2 spastic paraplegia 16, x-linked 10.4 WASHC5 SPAST
3 hereditary spastic paraplegia 72 10.4 SPAST REEP1
4 spastic ataxia 2 10.4 REEP1 KIF1A
5 spastic paraplegia 14, autosomal recessive 10.4 WASHC5 SPAST
6 neuropathy, hereditary sensory, type iic 10.4 REEP1 KIF1A
7 spastic paraplegia 5a, autosomal recessive 10.4 SPG7 SPAST
8 spastic paraplegia 61, autosomal recessive 10.4 SPAST REEP1
9 spastic paraplegia 57, autosomal recessive 10.3 SACS REEP1 KIF1A
10 spastic paraplegia 33, autosomal dominant 10.3 WASHC5 SPAST REEP1
11 spastic paraplegia 12, autosomal dominant 10.3 WASHC5 SPAST REEP1
12 spastic paraplegia 39, autosomal recessive 10.3 WASHC5 SPAST DDHD1
13 spastic paraplegia 48, autosomal recessive 10.3 WASHC5 SPAST REEP1
14 spastic paraplegia 47, autosomal recessive 10.3 WASHC5 REEP1
15 spastic ataxia 10.3 SPG7 SACS KIF1A
16 spastic paraplegia 26, autosomal recessive 10.3 WASHC5 SPAST REEP1
17 autosomal dominant non-syndromic intellectual disability 9 10.3 TECPR2 REEP1 KIF1A
18 spastic paraplegia 28, autosomal recessive 10.3 SPG7 REEP1 DDHD1
19 spastic paraplegia 54, autosomal recessive 10.3 SPG7 REEP1 DDHD1
20 spastic paraplegia 17, autosomal dominant 10.3 WASHC5 SPAST REEP1
21 spastic paraplegia 49, autosomal recessive 10.3 TECPR2 DDHD1
22 spastic paraplegia 3, autosomal dominant 10.3 WASHC5 SPAST REEP1
23 spastic paraplegia 35, autosomal recessive 10.3 WASHC5 SPG7 REEP1
24 spastic paraplegia 46, autosomal recessive 10.3 SPG7 DDHD1
25 spastic paraplegia 43, autosomal recessive 10.3 SPAST DDHD1
26 spastic paraplegia 7, autosomal recessive 10.3 SPG7 SACS
27 spastic paraplegia 30, autosomal recessive 10.2 WASHC5 SPAST REEP1 KIF1A
28 spastic paraplegia 6, autosomal dominant 10.2 WASHC5 SPAST REEP1 KIF1A
29 spastic paraplegia 8, autosomal dominant 10.2 WASHC5 SPAST REEP1 KIF1A
30 spastic paraplegia 31, autosomal dominant 10.2 WASHC5 SPG7 SPAST REEP1
31 spastic paraplegia 42, autosomal dominant 10.2 WASHC5 SPAST REEP1 KIF1A
32 spastic paraplegia 2, x-linked 10.2 WASHC5 SPG7 SPAST REEP1
33 spastic paraplegia 13, autosomal dominant 10.2 SPG7 SPAST REEP1 DDHD1
34 spastic paraplegia 18, autosomal recessive 10.2 WASHC5 SPG7 REEP1 DDHD1
35 spastic paraplegia 76, autosomal recessive 10.1 SPG7 CAPN1
36 spastic paraplegia 10, autosomal dominant 10.1 WASHC5 SPG7 SPAST REEP1 KIF1A
37 masa syndrome 10.0 WASHC5 SPG7 SPAST REEP1 KIF1A
38 spastic paraplegia 15, autosomal recessive 10.0 WASHC5 TECPR2 SPG7 SPAST REEP1
39 spastic paraparesis 10.0 TECPR2 SPG7 SPAST KIF1A DDHD1
40 hereditary ataxia 10.0 SPG7 SACS CAPN1
41 spastic paraplegia 20, autosomal recessive 10.0 SPG7 SPAST
42 spastic paraplegia 4, autosomal dominant 9.9 WASHC5 SPG7 SPAST SACS REEP1 KIF1A
43 visual epilepsy 9.8 STXBP1 SPG7 SPAST SLC2A1
44 paraplegia 9.5 WASHC5 TECPR2 SPG7 SPAST REEP1 KIF1A
45 hereditary spastic paraplegia 9.1 WASHC5 TECPR2 SPG7 SPAST SLC2A1 SACS
46 microcephaly 8.6 UFC1 STXBP1 SLC2A1 SLC1A4 PLAA PCDH12

Graphical network of the top 20 diseases related to Spasticity:

Diseases related to Spasticity

Symptoms & Phenotypes for Spasticity

MGI Mouse Phenotypes related to Spasticity:

# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 9.36 ATP6AP2 DARS1 KIF1A KIF7 PLAA REEP1

Drugs & Therapeutics for Spasticity

Drugs for Spasticity (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 296)
# Name Status Phase Clinical Trials Cas Number PubChem Id
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
Ethanol Approved Phase 4 64-17-5 702
Clonidine Approved Phase 4 4205-90-7 2803
Memantine Approved, Investigational Phase 4 19982-08-2 4054
Oxycodone Approved, Illicit, Investigational Phase 4 76-42-6 5284603
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
Norepinephrine Approved Phase 4 51-41-2 439260
Chlorzoxazone Approved Phase 4 95-25-0 2733
Acetaminophen Approved Phase 4 103-90-2 1983
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Hydromorphone Approved, Illicit Phase 4 466-99-9 5284570
12 Acetylcholine Release Inhibitors Phase 4
13 Botulinum Toxins Phase 4
14 Cholinergic Agents Phase 4
15 Botulinum Toxins, Type A Phase 4
16 Anti-Infective Agents Phase 4
17 Anti-Infective Agents, Local Phase 4
18 Sympathomimetics Phase 4
19 Dihydroxyphenylalanine Phase 4
20 Liver Extracts Phase 4
21 incobotulinumtoxinA Phase 4
22 Psychotropic Drugs Phase 4
23 Analgesics Phase 4
24 Adrenergic alpha-2 Receptor Agonists Phase 4
25 Adrenergic Agonists Phase 4
26 Anticonvulsants Phase 4
27 Sympatholytics Phase 4
28 Adrenergic Agents Phase 4
29 Central Nervous System Depressants Phase 4
30 rimabotulinumtoxinB Phase 4
31 Anti-Anxiety Agents Phase 4
32 Tranquilizing Agents Phase 4
33 Antimanic Agents Phase 4
34 Excitatory Amino Acids Phase 4
35 Excitatory Amino Acid Antagonists Phase 4
36 Antidepressive Agents Phase 4
37 Narcotics Phase 4
38 Analgesics, Opioid Phase 4
39 Venlafaxine Hydrochloride Phase 4
40 Serotonin and Noradrenaline Reuptake Inhibitors Phase 4
41 Neuromuscular Agents Phase 4
42 Melanocyte-Stimulating Hormones Phase 4
43 beta-endorphin Phase 4
44 Adrenocorticotropic Hormone Phase 4
Serotonin Investigational, Nutraceutical Phase 4 50-67-9 5202
Miconazole Approved, Investigational, Vet_approved Phase 2, Phase 3 22916-47-8 4189
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
Amantadine Approved Phase 2, Phase 3 768-94-5 2130
Pentoxifylline Approved, Investigational Phase 3 6493-05-6 4740
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 2, Phase 3 437-38-7 3345

Interventional clinical trials:

(show top 50) (show all 778)
# Name Status NCT ID Phase Drugs
1 Phase III Study of Botulinum Toxin A Injection for Lower Limbs Spasticity in Subacute Stroke Adults Unknown status NCT02505802 Phase 4 BoNT-A injection
2 Upper Extremity Rehabilitation Using Robot and Botulinum Toxin Unknown status NCT02228863 Phase 4
3 Antispastic Effect of Transcranial Magnetic Stimulation in Patients With Cerebral and Spinal Spasticity Unknown status NCT01786005 Phase 4
4 A Randomized Controlled Trial of Rectus Femoris Tenotomy Versus Botulinum Toxin A for Stiff Knee Gait After Stroke Unknown status NCT02114736 Phase 4 Botulinum Toxin injection in the rectus femoris muscle
5 The Impact of Botulinum Toxin Treatment in Quality of Life of Cervical Dystonia Patients Unknown status NCT01664013 Phase 4 Nuronox
6 Functional Electrical Stimulation-Assisted Walking: Reduction of Secondary Complications Due to Spinal Cord Injury Unknown status NCT00201968 Phase 4
7 Effects of Functional Electrical Stimulation on Gait in Children With Hemiplegic and Diplegic Cerebral Palsy Unknown status NCT02462018 Phase 4
8 Dopamine Treatment in Children With Cerebral Palsy With Dystonia- A Double Blind Controlled Study Unknown status NCT01361373 Phase 4 L- DOPA;placebo
9 Treatment for Alcohol Dependence With Gabapentin: A Double Blind Placebo Controlled Randomized Clinical Trial Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
10 An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids Unknown status NCT01583478 Phase 4
11 Impact of Injection Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity Completed NCT02757404 Phase 4 Ultrasonography guidance injection of Meditoxin®.;Electrical stimulation guidance injection of Meditoxin®.;Manual needle placement injection of Meditoxin®.
12 A Prospective, Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of MEDITOXIN® in Treatment of Post Stroke Upper Limb Spasticity Completed NCT03908580 Phase 4 Meditoxin
13 A 24-week Prospective, Multicentre, Randomised, Double-blind, Placebo Controlled Study of Dysport® Injection for the Treatment of Upper Limb Spasticity in Early Stroke. Completed NCT00234546 Phase 4 Placebo
14 A Prospective Phase IV, Multicentre, Placebo-controlled Study to Demonstrate Changes in the Quality of Life Following DYSPORT Intramuscular Injection in the Treatment of Upper Limb Spasticity in Adult Post-Stroke Patients Completed NCT00216411 Phase 4 Placebo
15 Asian Multicentre, Double Blind, Randomised, Placebo Controlled Pilot Study, to Assess the Impact of Dysport® Intramuscular Injections When Administered Within the First 12 Weeks After Stroke on the Time to Spasticity Progression in Adult Subjects With Upper Limb (UL) Spasticity. Completed NCT02321436 Phase 4 Placebo
16 BOTOX® Economic Spasticity Trial (BEST) Completed NCT00549783 Phase 4
17 Hand Rehabilitation Using Botulinum Toxin and Functional Electrical Stimulation Among Stroke Patients With Limitation of Finger Extension Due to Spasticity- Pilot Study Completed NCT03549975 Phase 4 Botulinum Toxin Type A 100 unit/Vial (Product)
18 A Multicentre, Double-blind, Randomised, Parallel Group, Placebo-controlled Study of the Effect of Long-term Treatment With Sativex on Cognitive Function and Mood of Patients With Spasticity Due to Multiple Sclerosis Completed NCT01964547 Phase 4 Sativex;Placebo
19 Vanderbilt University Spasticity Management Program Evaluation Plan Completed NCT00179114 Phase 4 Botulinum Toxin Type A;Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)
20 Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity Completed NCT00178646 Phase 4 Botox
21 Multi-center, Single Arm, Open-label, Phase IV Clinical Trial to Evaluate the Safety and Efficacy of MEDITOXIN® in Children With Cerebral Palsy Completed NCT01256021 Phase 4 Botulinum Toxin Type A
22 Myobloc Atrophy Study Completed NCT02052024 Phase 4 Botox;MYOBLOC
23 A Randomized, Controlled, Open-label, Parallel-group, Multi-center Study to Compare the Effect of Intrathecal Baclofen Therapy Versus Best Medical Treatment on Severe Spasticity in Post-stroke Patients After 6 Months Active Treatment Completed NCT01032239 Phase 4 intrathecal baclofen
24 A Randomized Controlled Trial on Effects of Botulinum Toxin Type A in Adults With Cerebral Palsy Completed NCT00432055 Phase 4 Botulinum toxin type A (Botox);placebo (saline)
25 Placebo-Controlled Trial of BOTOX® Versus Zanaflex® for the Treatment of Subjects With Post Stroke Upper Limb Spasticity Completed NCT00430196 Phase 4 BOTOX®;Zanaflex®
26 Memantine for Spasticity in MS Patients Completed NCT00638027 Phase 4 placebo;memantine
27 Effects of Repeated Use of Botulinum Neurotoxin Type A (BoNT/A) Free of Complexing Proteins in the Spastic Equinovarus Foot in Stroke Patients: A Randomized Clinical Trial Completed NCT03044080 Phase 4 IncobotulinumtoxinA;OnabotulinumtoxinA
28 An Efficacy Comparison of Botulinum Toxin A Injection Into Two Different Sites in Gastrocnemius Muscle for the Treatment of Spastic Patients, Randomized Controlled Trial Completed NCT01278576 Phase 4 BOTOX-A®
29 Recurrent Crying Spells in Cerebral Palsy With Spastic Quadriparesis - A Crossover Study Completed NCT01955655 Phase 4 Baclofen
30 A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Incobotulinumtoxin Type A for the Functional Improvement of Lower Extremity Spasticity in Patients With Multiple Sclerosis Completed NCT01968902 Phase 4
31 An International, Multicentre, Prospective, Single-Arm Study to Assess the Effect on Voluntary Movements of AbobotulinumtoxinA 1500 U Administered in Both Upper and Lower Limbs in Conjunction With a Guided Self-Rehabilitation Contract in Adult Subjects With Spastic Hemiparesis Completed NCT02969356 Phase 4
32 Measuring the Functional Effects of Botox on the Brain Using MR Spectroscopy and fMRI Completed NCT03373162 Phase 4 onabotulinumtoxinA
33 Preemptive Single Dose Tizanidine and Ultrasound Guided Superficial Cervical Block on Pain After Thyroidectomy Completed NCT02725359 Phase 4 Placebo;Tizanidine;Bupivacaine;Saline
35 Botulinum Toxin A for the Treatment of Cervical/Shoulder Pain Following Acute Spinal Cord Injury. Completed NCT00320281 Phase 4 botulinum toxin A
36 A Controlled Trial of Venlafaxine XR for Major Depression After Spinal Cord Injury: A Multi-site Study Completed NCT00592384 Phase 4 venlafaxine XR;placebo
37 Analgetic Effects of Chlorzoxazone in Total Hip and Knee Arthroplasty Completed NCT02405104 Phase 4 chlorzoxazone;Placebo
38 Does Postoperative Gabapentin Reduce Pain, Opioid Consumption & Anxiety & Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy? Completed NCT00982800 Phase 4 Gabapentin;Placebo Sugar Pill
39 Optimal Dose of Extracorporeal Shock Wave Therapy After Botulinum Toxin Type A Injection for Post-stroke Spasticity Recruiting NCT02358005 Phase 4
40 Dose-response Relationship of Botullinum Toxin (DWP 450) for Finger Flexor Spasticity Recruiting NCT03517319 Phase 4 Normal Saline 0.9% 1.2 ml;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 15 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 30 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 50 U;Clostridium Botulinum Toxin Type A (Nabota, DWP 450) 70 U
41 Randomised Controlled Trial to Evaluate the Effect of a Self-rehabilitation Program in Addition to Usual Treatment for Spasticity (Repeated Botulinum Toxin Injections and Physiotherapy) on Impairment and Activity Limitation in Patients With Spastic Hemiparesis Following Stroke Recruiting NCT02944929 Phase 4
42 Imaging of 3D Innervation Zone Distribution in Spastic Muscles From High-density Surface Recruiting NCT03302741 Phase 4 Botulinum neurotoxin (BTX)
43 Study of the Effects on Motor Recovery of Early Post-stroke Spasticity Treatment: Double Blinded Comparison Between Botulinum Toxin and Baclofen. Recruiting NCT02462317 Phase 4 botulinum A toxin;Baclofen;Placebo toxin;placebo baclofen
44 The Movement of Botulinum Toxin Through the Lateral Gastrocnemius Muscle in Humans: An Expanded Examination Recruiting NCT03367429 Phase 4 Botox
45 Does Botulinum Toxin A Make Walking Easier in Children With Cerebral Palsy? Recruiting NCT02546999 Phase 4 botox;placebo
46 Short and Long Term Fampridine Treatment in Persons With Multiple Sclerosis: Cognitive and Motor Performances Recruiting NCT02849782 Phase 4 Fampridine
47 Intrathecal (IT) Baclofen Drug Distribution Pilot Study Active, not recruiting NCT02903823 Phase 4 Baclofen bolus injection
48 Botulinum Toxin Pyloroplasty to Reduce Postoperative Nausea and Vomiting After Sleeve Gastrectomy Enrolling by invitation NCT03701919 Phase 4 Botulinum toxin pyloroplasty;Normal saline pyloric injection
49 Research Assistant Doctor Not yet recruiting NCT03860662 Phase 4 Botox;Baclofen
50 Randomised, Evaluation-blinded, Crossover, Controlled Study Assessing the Antispastic Efficacy and Safety of Dynamic Night Hand Splinting in Adults With Post-stroke Hemiplegia Treated by Botulimum Toxin (Dysport®) - (a Pilot Study) Not yet recruiting NCT02888548 Phase 4

Search NIH Clinical Center for Spasticity

Genetic Tests for Spasticity

Genetic tests related to Spasticity:

# Genetic test Affiliating Genes
1 Spasticity 29

Anatomical Context for Spasticity

MalaCards organs/tissues related to Spasticity:

Spinal Cord, Brain, Testes, Bone, Skeletal Muscle, Cortex, T Cells

Publications for Spasticity

Articles related to Spasticity:

(show top 50) (show all 10946)
# Title Authors PMID Year
Transcranial direct current stimulation associated with physical-therapy in acute stroke patients - A randomized, triple blind, sham-controlled study. 61
31735645 2020
The Hemisection Approach in Large Animal Models of Spinal Cord Injury: Overview of Methods and Applications. 61
30380340 2020
Cancer Rehabilitation:: Acute and Chronic Issues, Nerve Injury, Radiation Sequelae, Surgical and Chemo-Related, Part 2. 61
32035567 2020
Spasticity and pain in adults with cerebral palsy. 61
31602643 2020
Pain in adults with cerebral palsy: measuring the contribution of spasticity. 61
31696934 2020
Truncating variants in UBAP1 associated with childhood-onset nonsyndromic hereditary spastic paraplegia. 61
31696996 2020
Italian consensus on treatment of spasticity in multiple sclerosis. 61
31652369 2020
Cannabis Use in Children With Pantothenate Kinase-Associated Neurodegeneration. 61
31823681 2020
Phosphoserine aminotransferase deficiency: imaging findings in a child with congenital microcephaly. 61
30122079 2020
The effectiveness of extracorporeal shock wave therapy to reduce lower limb spasticity in stroke patients: a systematic review and meta-analysis. 61
31710277 2020
An Omnidirectional Assistive Platform Integrated with Functional Electrical Stimulation for Gait Rehabilitation: A Case Study. 61
32031944 2020
Selective dorsal rhizotomy: an illustrated review of operative techniques. 61
32032949 2020
Effect of Additional Rehabilitation After Botulinum Toxin-A on Upper Limb Activity in Chronic Stroke: The InTENSE Trial. 61
31813359 2020
Acute and Chronic Pain in Children and Adolescents With Cerebral Palsy: Prevalence, Interference, and Management. 61
31521713 2020
Botulinum Toxin in Children with Cerebral Palsy: An Update. 61
31486052 2020
Surgical Tone Reduction in Cerebral Palsy. 61
31760996 2020
Sex may influence motor phenotype in a novel rodent model of cerebral palsy. 61
31841677 2020
Principles of Ankle-Foot Orthosis Prescription in Ambulatory Bilateral Cerebral Palsy. 61
31760995 2020
The role of selective dorsal rhizotomy in the management of post-traumatic spasticity: systematic review. 61
32020384 2020
Spasticity and Pain after Spinal Cord Injury: Impact on Daily Life and the Influence of Psychological Factors. 61
31298813 2020
AbobotulinumtoxinA and rehabilitation vs rehabilitation alone in post-stroke spasticity: A cost-utility analysis. 61
31820010 2020
Inequalities in pharmacologic treatment of spasticity in Sweden - health economic consequences of closing the treatment gap. 61
32030530 2020
Post hoc analysis of shoulder spasticity and safety following treatment with incobotulinumtoxinA. 61
32025741 2020
Transcutaneous Spinal Cord Stimulation Induces Temporary Attenuation of Spasticity in Individuals with Spinal Cord Injury. 61
31333064 2020
[Analysis of the concept of the Zika Virus congenital syndrome]. 61
32022196 2020
Transcranial Magnetic Stimulation as Treatment in Multiple Neurologic Conditions. 61
32020300 2020
Squalene Synthase Deficiency 61
32027475 2020
Predictive Model for Gastrostomy Placement in Adolescents With Developmental Disabilities and Cerebral Palsy. 61
31134674 2020
Pain and the immune system: emerging concepts of IgG-mediated autoimmune pain and immunotherapies. 61
30224548 2020
Very-late-onset Friedreich's ataxia: diagnosis in a kindred with late-onset cerebellar ataxia. 61
31467149 2020
POLR3A-related spastic ataxia: new mutations and a look into the phenotype. 61
31637490 2020
Genetic and phenotypic characterization of NKX6-2-related spastic ataxia and hypomyelination. 61
31509304 2020
Construct Validity of the Observable Movement Quality Scale in Pediatrics: Hypothesis Testing of a Formative Measurement Model. 61
32031656 2020
Children with uncontrolled asthma and significant reversibility might show hypoxaemia. 61
32020332 2020
Is Thoracodorsal Nerve Transection Needed in Latissimus Dorsi Breast Reconstruction? 61
32028468 2020
Poststroke Postural Sway Improved by Botulinum Toxin: A Multicenter Randomized Double-blind Controlled Trial. 61
31469982 2020
Effects of a Robot-Assisted Arm Training Plus Hand Functional Electrical Stimulation on Recovery After Stroke: A Randomized Clinical Trial. 61
31678222 2020
Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation (rTMS): An update (2014-2018). 61
31901449 2020
The effectiveness and safety of extracorporeal shock wave therapy (ESWT) on spasticity after upper motor neuron injury: A protocol of systematic review and meta-analysis. 61
32028402 2020
Effects of a 3D-printed orthosis compared to a low-temperature thermoplastic plate orthosis on wrist flexor spasticity in chronic hemiparetic stroke patients: a randomized controlled trial. 61
31686529 2020
Cost effectiveness and impact on quality of life of abobotulinumtoxinA and onabotulinumtoxinA in the treatment of children with lower limb spasticity in Canada. 61
31985313 2020
Effects of pressure garment on spasticity and function of the arm in the early stages after stroke: a randomized controlled trial. 61
32037862 2020
Characterization of absorbed and produced constituents in goat plasma urine and faeces from the herbal medicine Gelsemium elegans by using high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. 61
31988014 2020
The Void in Clinician Counseling of Cannabis Use. 61
31898125 2020
Simultaneous Quantitation of S(+)- and R(-)-Baclofen and Its Metabolite in Human Plasma and Cerebrospinal Fluid using LC-APCI-MS/MS: An Application for Clinical Studies. 61
31936209 2020
Fugl-Meyer Assessment Scores Are Related With Kinematic Measures in People with Chronic Hemiparesis after Stroke. 61
31740027 2020
Is a hip flip the right trick? 61
31628149 2020
Cannabinoids in the Older Person: A Literature Review. 61
31941020 2020
Preferred options and evidence for upper limb surgery for spasticity in cerebral palsy, stroke, and brain injury. 61
31594425 2020
Change in popliteal angle and hamstrings spasticity during childhood in ambulant children with spastic bilateral cerebral palsy. A register-based cohort study. 61
31914961 2020

Variations for Spasticity

ClinVar genetic disease variations for Spasticity:

6 (show all 11) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 46;XX;inv(2)(p23q31.3)inversion Pathogenic 267874
2 STXBP1 NM_001032221.6(STXBP1):c.116_118dup (p.Arg39dup)duplication Pathogenic 633836 9:130416019-130416020 9:127653740-127653741
3 KIF7 NM_198525.3(KIF7):c.434A>C (p.Tyr145Ser)SNV Pathogenic/Likely pathogenic 374124 rs758361736 15:90193067-90193067 15:89649836-89649836
4 46;XY;t(4;14;4;1)(q28.2;q13.1;28.2q21;p32.3)dnTranslocation Likely pathogenic 267905
5 CREBBP NM_001079846.1(CREBBP):c.6071_6081del (p.Ile2024fs)deletion Likely pathogenic 523472 rs1555471098 16:3778853-3778863 16:3728852-3728862
6 REEP1 NM_001164731.2(REEP1):c.524A>G (p.Ter175Trp)SNV Conflicting interpretations of pathogenicity 242633 rs587781248 2:86444224-86444224 2:86217101-86217101
7 SPAST NM_014946.3(SPAST):c.1276C>T (p.Leu426Phe)SNV Conflicting interpretations of pathogenicity 448444 rs1060502227 2:32361662-32361662 2:32136593-32136593
8 COL6A2 NM_001849.3(COL6A2):c.2008A>G (p.Thr670Ala)SNV Uncertain significance 598977 rs753298014 21:47545737-47545737 21:46125823-46125823
9 46;XX;inv(6)(p24q11)dninversion Uncertain significance 267935
10 PMP22 NM_000304.4(PMP22):c.422T>G (p.Val141Gly)SNV Uncertain significance 373965 rs1057518804 17:15134295-15134295 17:15230978-15230978
11 CACNA1A NM_001127221.1(CACNA1A):c.6128C>T (p.Thr2043Met)SNV Uncertain significance 386521 rs563345694 19:13323262-13323262 19:13212448-13212448

Expression for Spasticity

Search GEO for disease gene expression data for Spasticity.

Pathways for Spasticity

GO Terms for Spasticity

Cellular components related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 axon GO:0030424 9.46 STXBP1 SACS KIF1A ATP6AP2
2 extracellular exosome GO:0070062 9.32 UFC1 STXBP1 SPAST SLC2A1 SLC1A4 PLAA
3 axon cytoplasm GO:1904115 9.13 SPG7 SPAST KIF1A

Biological processes related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 anterograde axonal transport GO:0008089 8.8 SPG7 SPAST KIF1A

Molecular functions related to Spasticity according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 microtubule binding GO:0008017 8.92 SPAST REEP1 KIF7 KIF1A

Sources for Spasticity

9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
31 HPO
32 ICD10
33 ICD10 via Orphanet
37 LifeMap
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
54 Novoseek
57 OMIM via Orphanet
61 PubMed
70 Tocris
72 UMLS via Orphanet
Loading form....